Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CDC25B | P30305 | 6/20 | 0.55 |
| ▸ | CDC25A | P30304 | 5/20 | 0.55 |
| ▸ | S100A4 | P26447 | 4/20 | 0.55 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5820931 | 0.86 | FGFR1 (0.57) | MAPTALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL30004167 | 0.86 | FGFR1 (0.57) | MAPTALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL5820368 | 0.84 | MAPT (0.58) | MAPTALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL5810540 | 0.84 | TBXAS1 (0.62) | MAPTALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL571005 | 0.83 | MAPT (0.53) | MAPTALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL12761938 | 0.81 | TBXAS1 (0.59) | MAPTALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL13649286 | 0.81 | MAPT (0.54) | MAPTALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL10446741 | 0.81 | MAPT (0.59) | MAPTALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL3271230 | 0.81 | AURKA (0.55) | MAPTALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL707464 | 0.81 | MAPT (0.54) | MAPTALDH1A1LMNAL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022265178-A1 | TRAP1 INHIBITOR AND USE THEREOF | 주식회사 스마틴바이오 | 2022-12-22 | — | — | WO | disclosed |
| US-20220348530-A1 | Menaquinol Compositions and Methods of Treatment | Epizon Pharma, Inc. (US) | 2022-11-03 | — | — | US | disclosed |
| US-11332427-B2 | Menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210171489-A1 | SYNTHESIS OF CHROMANOL AND 2-METHYL-1,4-NAPHTHOQUINONE DERIVATIVES | BASF SE (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20210009494-A1 | Menaquinol Compositions and Methods of Treatment | Epizon Pharma, Inc. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10822295-B2 | Menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| WO-2015183985-A2 | THERAPEUTIC COMPOSITIONS INCLUDING NAPHTHOQUINONES AND USES THEREOF | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2015-12-03 | — | — | WO | disclosed |
| WO-2014063923-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | NICOX S.A. (FR) | 2014-05-01 | — | — | WO | disclosed |
| US-20130345312-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES | BIOELECTRON TECHNOLOGY CORPORATION | 2013-12-26 | — | — | US | disclosed |
| EP-2600857-A2 | TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES | Edison Pharmaceuticals, Inc. (US) | 2013-06-12 | — | — | EP | disclosed |
| US-20090176805-A1 | DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS | CRONYN MARSHALL W | 2009-07-09 | — | — | US | disclosed |
| US-20090176805-A1 | DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS | CRONYN MARSHALL W | 2009-07-09 | — | — | US | disclosed |
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070208086-A1 | UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070203080-A1 | New Drug Delivery System for Crossing the Blood Brain Barrier | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-30 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| EP-0597890-B1 | REMOVAL OF HYDROGEN SULPHIDE | SOLVAY INTEROX LTD (GB) | 1997-03-12 | — | — | EP | disclosed |
| US-5545391-A | Removal of hydrogen sulphide | SOLVAY INTEROX LIMITED (GB) | 1996-08-13 | — | — | US | disclosed |
| EP-0597890-A1 | REMOVAL OF HYDROGEN SULPHIDE. | SOLVAY INTEROX LTD (GB) | 1994-05-25 | — | — | EP | disclosed |
| WO-1993002961-A1 | REMOVAL OF HYDROGEN SULPHIDE | SOLVAY INTEROX LIMITED (GB) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009494-A1 | Menaquinol Compositions and Methods of Treatment | SDHA, SDHB, NDUFB7 | MAPT 3333/4885ALDH1A1 762/4885LMNA 373/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | MAPT 1883/4885ALDH1A1 2811/4885LMNA 1374/4885 |
| US-20070208086-A1 | UBIQUINONE ANALOGS AND METHODS OF USE | NDUFB7, NDUFB1, NDUFB3 | MAPT 4254/4885ALDH1A1 638/4885LMNA 1593/4885 |
| US-20220348530-A1 | Menaquinol Compositions and Methods of Treatment | SDHA, SDHB, NDUFB7 | MAPT 3333/4885ALDH1A1 762/4885LMNA 373/4885 |
| US-11332427-B2 | Menaquinol compositions and methods of treatment | SDHA, SDHB, NDUFB7 | MAPT 3333/4885ALDH1A1 762/4885LMNA 373/4885 |
| US-20130345312-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES | NDUFAB1, NDUFA2, NDUFS6 | MAPT 1223/4885ALDH1A1 714/4885LMNA 319/4885 |
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | MAPT 3931/4885ALDH1A1 530/4885LMNA 4176/4885 |
| US-10822295-B2 | Menaquinol compositions and methods of treatment | PROC, VKORC1L1, VKORC1 | MAPT 2533/4885ALDH1A1 1954/4885LMNA 285/4885 |
| US-20210171489-A1 | SYNTHESIS OF CHROMANOL AND 2-METHYL-1,4-NAPHTHOQUINONE DERIVATIVES | CYP4B1, CYP2J2, CYP1A2 | MAPT 3703/4885ALDH1A1 772/4885LMNA 729/4885 |
| US-20090176805-A1 | DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS | MGMT, ETV6, EI24 | MAPT 4552/4885ALDH1A1 2643/4885LMNA 4554/4885 |
| US-20070203080-A1 | New Drug Delivery System for Crossing the Blood Brain Barrier | NDUFB5, NDUFB7, NDUFB3 | MAPT 1404/4885ALDH1A1 991/4885LMNA 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.